Drug Trial Radar · NCT05938946
Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Aug 30, 2023
Primary completion
Sep 2, 2024
Study completion Sep 2, 2024
Sponsor
- Lead sponsor
- Pharmosa Biopharm Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Jul 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.
Conditions
- Pulmonary Arterial Hypertension
Interventions
L608 Inhalation SolutionDrug
subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
Placebo solutionDrug
subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of dose limiting toxicity (DLT)Time frame: Baseline to Day 14
- The incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Baseline to Day 21
- Frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Baseline to Day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.